Your browser doesn't support javascript.
loading
Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials.
Sakai, Soichi; Kaku, Kohei; Seino, Yutaka; Inagaki, Nobuya; Haneda, Masakazu; Sasaki, Takashi; Fukatsu, Atsushi; Kakiuchi, Haruka; Samukawa, Yoshishige.
Afiliación
  • Sakai S; Taisho Pharmaceutical Co., Ltd., Tokyo, Japan. Electronic address: so-sakai@so.taisho.co.jp.
  • Kaku K; Department of Internal Medicine, Kawasaki Medical School, Okayama, Japan.
  • Seino Y; Kansai Electric Power Hospital, Osaka, Japan.
  • Inagaki N; Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Haneda M; Division of Metabolism and Biosystemic Science, Department of Medicine, Asahikawa Medical University, Hokkaido, Japan.
  • Sasaki T; Institute of Clinical Medicine and Research, The Jikei University School of Medicine, Chiba, Japan.
  • Fukatsu A; Yachiyo Hospital, Aichi, Japan.
  • Kakiuchi H; Taisho Pharmaceutical Co., Ltd., Tokyo, Japan.
  • Samukawa Y; Taisho Pharmaceutical Co., Ltd., Tokyo, Japan.
Clin Ther ; 38(4): 843-862.e9, 2016 Apr.
Article en En | MEDLINE | ID: mdl-27021608

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sorbitol / Diabetes Mellitus Tipo 2 / Hipoglucemiantes Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Clin Ther Año: 2016 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sorbitol / Diabetes Mellitus Tipo 2 / Hipoglucemiantes Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Clin Ther Año: 2016 Tipo del documento: Article Pais de publicación: Estados Unidos